These observations collectively suggest that targeting the RFX6–PGAM1 axis might be a tempting option for the treatment of HCC, not only by restricting energy supply but also by impeding anabolic processes essential for tumour cell proliferation, thereby ‘killing two birds with one stone’.41 The gene discussed is RFX6; the disease is neoplasm.